Summary

North America is the largest market for insulin delivery devices. The increased incidence of diabetes necessitates a robust market for insulin delivery devices as a crucial component of diabetes management. The region boasts an advanced healthcare infrastructure with well-established medical facilities, research institutions, and a network of healthcare professionals. This infrastructure supports the development, manufacturing, and distribution of insulin delivery devices. On-going research and development initiatives in the field of diabetes management are common in North America. This focus on innovation contributes to the development of more advanced and effective insulin delivery devices. Patient preferences for convenient and user-friendly insulin delivery devices are considered in product development. North American patients often favour devices that integrate seamlessly into their lifestyle, contributing to market demand. The presence of active diabetes advocacy groups and organizations in North America contributes to increased awareness, patient support, and initiatives that promote the use of advanced insulin delivery technologies. North America is a hub for diabetes research and clinical trials. The presence of leading research institutions and the conduct of extensive clinical studies contribute to the development and validation of new insulin delivery technologies. The aging population in North America contributes to the prevalence of diabetes, as diabetes incidence tends to be higher among older individuals. This demographic factor increases the demand for insulin delivery devices.

According to the research report "North America Insulin Delivery Devices Market Outlook, 2028," published by Bonafide Research, the insulin delivery devices market was valued more than USD 6 Billion in 2022. Continued innovation in insulin delivery device technology, including the development of smart insulin pens, wearable devices, and integration with digital health platforms. This trend aimed to enhance user experience, improve dose accuracy, and provide additional features for diabetes management. The integration of insulin delivery devices with digital platforms and mobile applications for real-time data monitoring and sharing. Smart devices enable patients and healthcare providers to track insulin administration, glucose levels, and other relevant data remotely. A growing awareness of environmental sustainability has led to a focus on eco-friendly insulin delivery devices. Manufacturers are exploring materials and designs that reduce the environmental impact of device production and disposal. Exploration and development of wearable insulin delivery devices, such as insulin patches or wearable pumps. These devices offer discreet and continuous insulin delivery, providing an alternative to traditional injection methods. On-going adaptations influenced by the COVID-19 pandemic. The pandemic accelerated trends such as telehealth adoption and highlighted the importance of remote monitoring and virtual care in diabetes management. Integration of insulin delivery device data with electronic health records. This trend aims to create a more comprehensive patient profile, enabling healthcare providers to make informed decisions based on a holistic view of the patient's health.

According to the report based on country the market is segmented into United States, Canada and Mexico. The United States has one of the highest healthcare expenditures per capita globally. The willingness to invest in advanced healthcare technologies, including insulin delivery devices, contributes to the growth of the market. The substantial healthcare spending in the United States allows for significant investments in research and development. Pharmaceutical and medical device companies can allocate resources to conduct extensive R&D for the innovation and improvement of insulin delivery devices. This investment enables the development of advanced technologies, such as smart insulin pens, connected devices, and other innovations that enhance patient outcomes. High healthcare expenditures enable healthcare providers and organizations to adopt and integrate the latest technologies. In the context of insulin delivery devices, this means a greater willingness to adopt technologically advanced solutions that offer better patient management, improved adherence, and overall enhanced diabetes care. The availability of substantial funds contributes to the establishment and maintenance of a highly advanced healthcare infrastructure in the United States. This infrastructure supports the integration of advanced medical technologies, including insulin delivery devices, into the healthcare system. Hospitals, clinics, and healthcare providers can invest in and adopt the latest devices to ensure the delivery of high-quality care. In addition, Mexico has been making efforts to enhance its healthcare infrastructure. Investments in healthcare facilities, medical equipment, and technology contribute to the improved accessibility and availability of advanced medical devices, including insulin delivery devices. Changing lifestyles, urbanization, and dietary habits contribute to the rise of chronic diseases, including diabetes. As urban populations grow and lifestyles shift, there is an increased need for effective diabetes management solutions, including insulin delivery devices. Government initiatives and healthcare programs focused on diabetes management can stimulate the market for insulin delivery devices. Public health campaigns, educational programs, and subsidized healthcare services may contribute to increased awareness and adoption of these devices.

The market is segmented into Insulin Pens, Insulin Pumps, Insulin Pen Needles, Insulin Syringes and Others Insulin Delivery Devices (Insulin transdermal patches, insulin inhalers, insulin jet injection). Insulin pens are known for their user-friendly design, making them easy for patients to handle and self-administer. The simplicity of use, combined with features like pre-filled cartridges and disposable needles, enhances the overall patient experience. Patients, including those with limited dexterity, find insulin pens more convenient compared to traditional vial and syringe methods. Many insulin pens come equipped with dose memory and tracking features. These features help patients keep track of their insulin doses, promoting adherence to prescribed regimens. Dose memory features can be especially beneficial for individuals with complex dosing schedules, contributing to better diabetes management. Healthcare professionals find insulin pens relatively easy to train patients on. The straightforward mechanism of insulin pens simplifies the training process, enabling healthcare providers to efficiently educate patients on proper usage. This ease of training supports a smooth transition for patients from other insulin delivery methods to pens. Furthermore, the availability of both disposable and reusable pen needles provides flexibility for patients and healthcare providers. Disposable pen needles are convenient and eliminate the need for needle changes, while reusable pen needles offer a cost-effective and environmentally friendly option. This variety caters to diverse patient preferences. The market has seen the emergence of disposable insulin pens with integrated needles. These pens offer a complete, ready-to-use solution, eliminating the need for separate pen needles. The convenience of disposable pens with integrated needles contributes to their adoption among patients.

In addition based on indication the market is divided into Diabetes, Pregnancy, Cardiovascular Disorders & Hypertension, Respiratory Diseases, Hearing Disorders, Cancer, Movement Disorders, Wound Care and Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV). Increased awareness about the relationship between cardiovascular disorders, and hypertension may drive patients and healthcare providers to focus on comprehensive management strategies, including the use of insulin delivery devices. The healthcare industry is increasingly focusing on holistic approaches to managing chronic conditions like diabetes. Recognizing the interplay between diabetes and cardiovascular health, healthcare providers may prescribe insulin delivery devices that offer more precise control over blood glucose levels, reducing the risk of cardiovascular complications. Furthermore, Pregnancy can sometimes lead to gestational diabetes, a form of diabetes that occurs during pregnancy. Women with gestational diabetes may require insulin to manage their blood glucose levels and reduce the risk of complications for both the mother and the baby. The need for insulin during pregnancy can drive the demand for insulin delivery devices. The overall market for wearable health technologies, including insulin delivery devices, has been growing. Wearable insulin pumps and continuous glucose monitoring systems are examples of technologies that can be utilized not only in diabetes management but also in scenarios where precise insulin delivery is crucial, such as during pregnancy.

In terms of end user the market is segmented into Home Care, Hospitals & Clinics and Others. Hospitals play a significant role in inpatient diabetes management, especially for individuals with severe or acute conditions. Insulin delivery devices are commonly used in hospital settings to manage blood glucose levels in patients requiring insulin therapy. The inpatient setting contributes to the overall utilization of insulin delivery devices. Hospitals and clinics are increasingly integrating technology into healthcare delivery. This includes the use of electronic health records (EHRs), digital monitoring tools, and connected medical devices. Insulin delivery devices that seamlessly integrate with these technological advancements are more likely to be adopted in hospital settings, contributing to the anticipated growth.

The Insulin Delivery Devices Market in North America has been significantly influenced by the COVID-19 epidemic. Patients with type 1 diabetes are more affected by COVID-19. Due to their already compromised immune systems, people with diabetes quickly deteriorate when exposed to COVID-19. Compared to healthy persons, diabetics are more likely to experience major complications. With the assistance of local governments, insulin delivery device manufacturers have taken care to provide these devices to diabetic patients during COVID-19. Global medical professionals advised diabetics to monitor their blood sugar levels more frequently for safety reasons, and as a result, more people are taking medications, which have increased the need for insulin delivery systems. In North America, till April 2022, the United States had the highest number of COVID cases with more than 80 million; the country also registered the highest death rate. Diabetes patients in North America were more concerned with stocking up on monitoring and management gadgets, which led to a growth in the market over these years. In order to maintain minimal blood glucose levels, patients with Type 2 diabetes need to make numerous adjustments during the day, such as taking more insulin or eating more carbs. Moreover, patients who seek strict blood glucose control in an effort to avoid the long-term consequences linked to blood glucose variations are more likely to overcorrect and have hypoglycemia as a result. Without insulin pump therapy or many daily injections; it can be exceedingly difficult to achieve modest results.

Companies Covered in this report:

Novo Nordisk A/S , Sanofi S.A., Eli Lilly and Company, Medtronic plc , Terumo Corporation, Becton, Dickinson and Company, Insulet Corporation, Biocon Limited , Tandem Diabetes Care, Wockhardt Ltd., Medline Industries and many more.

Considered in this report:

• Geography: North America
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:

• North America Insulin Delivery Devices market with its value and forecast along with its segments
• Country-wise Insulin Delivery Devices market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Country Covered in this report:

• United States
• Canada
• Mexico

By Product

• Insulin Pens
• Insulin Pumps
• Insulin Pen Needles
• Insulin Syringes
• Others Insulin Delivery Devices (Insulin transdermal patches, insulin inhalers, insulin jet injection)

By Indication

• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Respiratory Diseases
• Hearing Disorders
• Cancer
• Movement Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

By End User

• Home Care
• Hospitals & Clinics
• Others

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Tea industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.





***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents